Supernus Pharmaceuticals Pre-Tax Profit Margin 2011-2024 | SUPN
Supernus Pharmaceuticals pre-tax profit margin from 2011 to 2024. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.
| Supernus Pharmaceuticals Pre-Tax Profit Margin Historical Data |
| Date |
TTM Revenue |
TTM Pre-Tax Income |
Pre-Tax Margin |
| 2024-09-30 |
$0.65B |
$0.07B |
11.04% |
| 2024-06-30 |
$0.63B |
$0.04B |
5.87% |
| 2024-03-31 |
$0.60B |
$-0.01B |
-1.00% |
| 2023-12-31 |
$0.61B |
$0.00B |
0.49% |
| 2023-09-30 |
$0.61B |
$0.04B |
6.06% |
| 2023-06-30 |
$0.63B |
$0.03B |
4.26% |
| 2023-03-31 |
$0.67B |
$0.06B |
8.23% |
| 2022-12-31 |
$0.67B |
$0.06B |
9.15% |
| 2022-09-30 |
$0.66B |
$0.03B |
4.25% |
| 2022-06-30 |
$0.63B |
$0.06B |
9.05% |
| 2022-03-31 |
$0.60B |
$0.08B |
12.81% |
| 2021-12-31 |
$0.58B |
$0.07B |
12.61% |
| 2021-09-30 |
$0.56B |
$0.11B |
19.68% |
| 2021-06-30 |
$0.57B |
$0.14B |
23.64% |
| 2021-03-31 |
$0.56B |
$0.15B |
27.11% |
| 2020-12-31 |
$0.52B |
$0.17B |
32.44% |
| 2020-09-30 |
$0.48B |
$0.17B |
35.64% |
| 2020-06-30 |
$0.42B |
$0.16B |
37.03% |
| 2020-03-31 |
$0.40B |
$0.15B |
38.06% |
| 2019-12-31 |
$0.39B |
$0.15B |
37.76% |
| 2019-09-30 |
$0.41B |
$0.15B |
35.78% |
| 2019-06-30 |
$0.41B |
$0.14B |
34.72% |
| 2019-03-31 |
$0.40B |
$0.13B |
32.92% |
| 2018-12-31 |
$0.41B |
$0.14B |
34.23% |
| 2018-09-30 |
$0.38B |
$0.14B |
35.70% |
| 2018-06-30 |
$0.36B |
$0.12B |
34.36% |
| 2018-03-31 |
$0.33B |
$0.12B |
34.43% |
| 2017-12-31 |
$0.30B |
$0.10B |
33.11% |
| 2017-09-30 |
$0.28B |
$0.08B |
29.35% |
| 2017-06-30 |
$0.25B |
$0.08B |
30.43% |
| 2017-03-31 |
$0.23B |
$0.06B |
27.07% |
| 2016-12-31 |
$0.22B |
$0.05B |
23.72% |
| 2016-09-30 |
$0.20B |
$0.04B |
21.32% |
| 2016-06-30 |
$0.18B |
$0.03B |
15.08% |
| 2016-03-31 |
$0.16B |
$0.02B |
11.66% |
| 2015-12-31 |
$0.15B |
$0.02B |
10.14% |
| 2015-09-30 |
$0.14B |
$0.01B |
8.89% |
| 2015-06-30 |
$0.12B |
$0.01B |
5.04% |
| 2015-03-31 |
$0.11B |
$0.01B |
5.31% |
| 2014-12-31 |
$0.09B |
$-0.01B |
-11.83% |
| 2014-09-30 |
$0.07B |
$-0.04B |
-51.39% |
| 2014-06-30 |
$0.05B |
$-0.06B |
-118.00% |
| 2014-03-31 |
$0.02B |
$-0.09B |
-445.00% |
| 2013-12-31 |
$0.01B |
$-0.09B |
-827.27% |
| 2013-09-30 |
$0.00B |
$-0.08B |
-4150.00% |
| 2013-06-30 |
$0.00B |
$-0.07B |
-7200.00% |
| 2013-03-31 |
$0.00B |
$-0.06B |
-5500.00% |
| 2012-12-31 |
$0.00B |
$-0.05B |
-4600.00% |
| 2012-09-30 |
$0.00B |
$-0.04B |
inf% |
| 2012-06-30 |
$0.00B |
$-0.04B |
inf% |
| 2012-03-31 |
$0.00B |
$-0.04B |
-3900.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$1.962B |
$0.608B |
|
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
|
